Abstract: An intravenous fluid conditioning system includes a housing having a first chamber and a second chamber. A volume of heat transfer medium is located in the first chamber and the second chamber. A first intravenous fluid line extends through the first chamber and a second intravenous fluid line extends through the second chamber. One or more thermoelectric devices are located in the housing, such that a first side of each of the one or more thermoelectric devices is in thermal communication with the first chamber and a second side of each of the one or more thermoelectric devices opposite the first side is in thermal communication with the second chamber. The one or more thermoelectric devices exchange thermal energy with a volume of intravenous fluid selectably flowed through the first intravenous fluid line or the second intravenous fluid line to condition the intravenous fluid.

Abstract: A method of manipulating and/or investigating cellular bodies (9) is provided. The method comprises the steps of: providing a sample holder (3) comprising a holding space (5) for holding a fluid medium (11); providing a sample (7) comprising one or more cellular bodies (9) in a fluid medium (11) in the holding space (5); generating an acoustic wave in the holding space exerting a force (F) on the sample (7) in the holding space (5). The method further comprises providing the holding space (5) with a functionalised wall surface portion (17) to be contacted by the sample (7) and the sample (7) is in contact with the functionalised wall surface portion (17) during at least part of the step of application of the acoustic wave. A system and a sample holder (3) are also provided.

Abstract: To provide a system capable of evaluating a deficiency and/or a lowered function of extrinsic coagulation factors or intrinsic coagulation factors with high sensitivity by adding new procedures and apparatuses to a blood coagulation system analysis procedure, an apparatus, or the like. A blood coagulation system analysis system includes a blood coagulation system measurement apparatus that performs blood coagulation system measurement of a blood sample; and a blood coagulation system analysis apparatus including a coagulation parameter extraction unit that extracts a coagulation parameter from a measurement result by the blood coagulation system measurement apparatus, and a blood coagulation evaluation unit that evaluates a level of blood coagulation of the blood sample on the basis of the coagulation parameter, the measurement by the blood coagulation system measurement apparatus being performed under an extrinsic system acceleration condition and an intrinsic system acceleration condition.

Abstract: A microchip for testing a blood property, comprising first and second channels for allowing a blood sample(s) to flow inside, wherein the first channel has a first reaction section coated with collagen and tissue thromboplastin; and said second channel has a second reaction section, wherein the second section has been coated with collagen and tissue thromboplastin the amount of which is equivalent to or smaller than the amount of tissue thromboplastin on said first channel, or the second section has been coated with collagen but not with tissue thromboplastin.

Abstract: The invention relates to a system for the early detection of life-threatening conditions of persons, wherein such risks exist, for example, due to a preceding operation. The system detects a plurality of vital parameters depending on the person to be monitored by means of a detector unit that is subsequently evaluated by an evaluation logic using a neuronal network. Individual parameters that exceed thresholds and constellations of parameters that represent a critical health condition of the person are displayed in different forms by means of a display device, depending on the risk. Said risk is determined in that the probability of the presence of a health anomaly is first determined and then evaluated.

Abstract: A device and method of using the device to detect the presence and composition of clots and other target objects in a circulatory vessel of a living subject is described. In particular, devices and methods of detecting the presence and composition of clots and other target objects in a circulatory vessel of a living subject using in vivo photoacoustic flow cytometry techniques is described.

Abstract: Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected.

Abstract: A blood coagulation analysis device and method in which information relating to the coagulability of blood is evaluated based on a change generated in a permittivity measured in a coagulation process of the blood due to addition of a substance that activates or inactivates platelets to the blood.

Abstract: Devices and methods for assessing coagulation include a channel configured such that shear stress, in a first portion of the channel, applied to blood drawn through the channel by a vacuum-tube attached to an outlet of the channel approximates physiological shear stresses.

Abstract: The invention includes systems, apparatuses and methods to evaluate the strength of clotting in addition to or separate from activated clotting time. The strength of clotting may be correlated with the amount of energy employed to move an object within blood. The strength of clotting may be correlated with the amount of time for fibrinolysis to occur. The strength of clotting may be determined by a system in which a ferromagnetic material is moved within blood.

Abstract: Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.

Abstract: A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyzer.

Abstract: The invention provides methods and compositions for determining whether a subject containing a stent immobilized in a blood vessel has asymptomatic stent thrombosis or is at risk of developing clinically symptomatic stent thrombosis. In one approach, the method involves imaging a region of the blood vessel that contains the stent using a probe that contains a fluorochrome, for example, a near-infrared fluorochrome, and a targeting moiety that binds a molecular marker indicative of the presence of asymptomatic stent thrombosis or the development of symptomatic stent thrombosis. To the extent that the subject displays one or more such markers, the probe binds to the markers and increases the local concentration of the probe in the vicinity of the stent. The imaging method identifies those patients that display a higher density of such markers in the vicinity of the stent. As a result, those patients can be monitored for, and/or treated to prevent, symptomatic stent thrombosis.

Abstract: Device, method, and computer program product for determining a material parameter of a blood coagulation cascade based on parameters of light diffused at a biofluid sample. In one example, the biofluid sample includes a blood sample. Laser light scattered by the sample is collected by the optical system in reflection and/or transmission mode. An image of the sample in so collected light is formed, and data representing fluctuations of laser speckle intensity with is processed to derive numerical descriptors associated with blood coagulation and fibrinolysis. In a specific case, such numerical descriptors are derived based on temporal dynamic of a viscoelastic characteristic of the blood sample.

Abstract: In order to provide a reagent kit for detecting LA which can clearly separate a lupus anticoagulant (LA)-positive specimen group from an LA-negative specimen group, it is configured that the reagent kit for detecting LA contains a first clotting time-measuring reagent and a second clotting time-measuring reagent and at least one of the first clotting time-measuring reagent and the second clotting time-measuring reagent contains alkali metal salt. The presence or absence of LA can be determined using the kit.

Abstract: A blood coagulation system analyzing method includes acquiring information relating to the coagulability of blood based on a change generated in a complex permittivity spectrum measured in a coagulation process of the blood due to addition of a substance that activates or inactivates platelets to the blood.

Abstract: The present invention provides for a clinical decision support system which makes use of a numerical model which dynamically describes a blood dilution of a blood circulation. Based on measured coagulation data and maybe other patient information, loss of hemostatic balance is predicted based on calculations of certain protein concentrations. Additionally, a calculation arrangement translates at least some of the calculated values of concentrations of human blood proteins into a risk value which risk value describes a risk of clotting and/or embolism and/or bleeding. A time development of that risk value is displayed to the user.

Abstract: Embodiments of the present invention relate to a system and method for in vivo measurement of blood parameters by processing analog electrical signals from a plurality of photodetectors. In some embodiments, it is possible to determine one or more blood parameters according to (i) a first electrical signal from a first detector and (ii) a second electrical signal from a second photodetector. A difference analog electrical signal is generated, indicative of a difference between the light response signal at the first location and light response signal at the second location, is generated. One or more blood parameters may be detected according to the difference analog electrical signal.

Abstract: A blood coagulation detection device includes a micro channel unit, an optical signal unit, an opto-electronic conversion circuit, an amplifier circuit, and a filter circuit. The micro channel unit has a sample detection area. The optical signal unit transmits a reference light to the micro channel unit so as to form a message light. The opto-electronic conversion circuit receives the message light and converts the message light into an electrical signal. The amplifier circuit is electrically connected to the opto-electronic conversion circuit for amplifying the electrical signal. The filter circuit is electrically connected to the amplifier circuit for filtering the amplified electrical signal.

Abstract: An optical blood coagulation monitor and method. The monitor has a blood sample holder, a laser with its output light directed through the blood sample, a two-dimensional detector that is able to detect light at the laser light wavelength and that has a detector output, optics for imaging onto the detector laser light that is forward scattered by the blood, and a data analysis system, responsive to the detector output, that is adapted to analyze the detected light to provide information on time-resolved coagulation and clotting properties of the blood.

Abstract: The present invention is directed to an integrated system and a method for utilizing the system to detect and remove blood-borne factors of interest, such as pathogens and/or toxins and/or cytokines, from blood or serum (blood) by contacting the blood with a solid, essentially nonporous substrate which has been surface treated with molecules or chemical groups (the adsorbent media or media) having a binding affinity for the pathogens and/or toxins to be removed (the adsorbents). The invention can be used to remove virulence factors, e.g. toxins, that are released from various pathogens. In one aspect, the invention is for the treatment of sepsis and infection, such as infections associated with battle field trauma.

Abstract: An assembly for testing platelet aggregation including an electrode subassembly that is mounted in a cuvette subassembly for use with relatively small samples containing platelets.

Abstract: A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyzer.

Abstract: A method of measuring blood clotting ability of a patient. A known volume of blood is dispensed on a reference disc of blotter paper, such that at least one reference blotch is formed on the reference disc. The surface area of the reference blotch formed on the reference disc, such that a relationship between the volume of blood and the surface area of the reference blotch can be obtained. An incision is made at the patient. A piece of blotter paper to the incision is applied to the incision to collect blood flowing therefrom, such that at least one blotch is formed on the piece of blotter paper. The surface area of the blotch formed on the piece of blotter paper is measured. The volume of the blood absorbed blood by the blotter paper is calculated according to the relationship between the blood volume and the surface area of the blotch.

Abstract: Methods, systems, and computer readable media for using actuated surface-attached posts for assessing biofluid rheology are disclosed. According to one aspect, a method for testing properties of a biofluid specimen includes placing the specimen onto a micropost array having a plurality of microposts extending outwards from a substrate, wherein each micropost includes a proximal end attached to the substrate and a distal end opposite the proximal end, and generating an actuation force in proximity to the micropost array to actuate the microposts, thereby compelling at least some of the microposts to exhibit motion. The method further includes measuring the motion of at least one of the microposts in response to the actuation force and determining a property of the specimen based on the measured motion of the at least one micropost.

Abstract: The present invention provides a reagent kit for detecting lupus anticoagulant which includes a first clotting time-measuring reagent containing manganese salt and a second clotting time-measuring reagent which contains manganese salt at a concentration lower than that of the first clotting time-measuring reagent or does not contain manganese salt and a method of determining the presence or absence of lupus anticoagulant using the kit.

Abstract: Methods, apparatus and systems for characterizing changes in at least one physical property of soft tissue. A series of acoustic pulses is generated and directed into the soft tissue such that at least one of the pulses is of sufficiently high intensity to induce physical displacement of the tissue. Waves reflected off the tissue, or a flexible member that moves with the tissue, are received and measured to estimate at least one characteristic of the physical displacement induced thereby. Repetition of the generating, receiving and estimating steps provides characterization of the at least one physical property over time. Methods, apparatus and systems for characterizing at least one physical property of blood, by generating a series of acoustic pulses and directing the series of pulses into the blood such that at least one of the pulses is of sufficiently high intensity to induce physical displacement of the blood.

Abstract: Methods and devices for conducting platelet aggregation analysis. A method for conducting platelet aggregation analysis by a cartridge device, including providing a blood sample in the cartridge device, stirring the blood sample within the cartridge device, measuring the electrical impedance between electrodes to obtain measured electrical impedance values, comparing measured electrical impedance values, discarding and repeating the measurements of the electrical impedance in case a variation of the measurements is outside a predetermined threshold range, or reporting the measured electrical impedance values in case the variation of the measurements is within the predetermined threshold range. Reported measured electrical impedance values indicate platelet aggregation in a blood sample.

Abstract: A system and method are presented for use in monitoring one or more conditions of a subject's body. The system includes a control unit which includes an input port for receiving image data, a memory utility, and a processor utility. The image data is indicative of data measured by a pixel detector array and is in the form of a sequence of speckle patterns generated by a portion of the subject's body in response to illumination thereof by coherent light according to a certain sampling time pattern. The memory utility stores one or more predetermined models, the model comprising data indicative of a relation between one or more measurable parameters and one or more conditions of the subject's body. The processor utility is configured and operable for processing the image data to determine one or more corresponding body conditions; and generating output data indicative of the corresponding body conditions.

Abstract: Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction with a blood sample of a living being. Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or an ISI, and may be carried out with the patient sample and a coagulation reagent, where the coagulation reagent may be selected from a number of coagulation reagents.

Abstract: An activated partial thromboplastin time measuring reagent, including a first reagent containing a phospholipid and an activator and a second reagent containing a herparin neutralizer and a calcium salt is disclosed. An activated partial thromboplastin time measuring method, and a determination method for determining a presence or absence of a blood coagulation inhibitor are also disclosed.

Abstract: A method of determining a prothrombin time is disclosed. A mediator is applied to a stratum corneum. The stratum corneum is penetrated to allow the mediator to enter a region containing interstitial fluid and interact with at least one capillary, causing blood and/or blood components to leak from the at least one capillary into the region containing interstitial fluid. A characteristic affected by the blood and/or blood components is measured in the region containing interstitial fluid which correlates to the prothrombin time. A system for measuring prothrombin time is also disclosed. The system has a mediator, one or more microneedles, and a processor directly or indirectly coupled to the one or more microneedles and configured to determine a coagulation change in blood or blood components in a region around the one or more microneedles after the one or more microneedles penetrate a stratum corneum.

Abstract: A system and method for initiating and maintaining a secure wireless communication between a wireless analyzer and a target network (e.g., a hospital network connected to a LIS and/or HIS). The present disclosure provides novel processes and systems for securely networking a wireless analyzer with a Wi-Fi network without the need for an operator or user to engage in manual initiation steps on, or through, the wireless analyzer.

Abstract: The present invention relates to an apparatus and method for optical measurement of a parameter related to motion of light-scattering particles within a fluid by manipulating analog electrical signals. In some embodiments, first and second analog signals are respectively obtained from first and second photodetectors respectively located at first and second locations. A technique is disclosed for boosting a fraction of an analog electrical signal attributable to light scattering fluctuations and/or to stochastic effects and/or to speckle measurements and/or to DLS measurements. According to this technique, a hybrid analog signal or a difference analog signals is obtained from the first and second analog signals, and is analyzed. Exemplary fluids include but are not limited to biological fluids (e.g. blood plasma). Teachings disclosed herein may be employed in vitro or in vivo.

Abstract: Methods and kits to determine thrombin activity are provided. They have the great advantage that there is no need to measure the whole calibrator curve in each individual medium, since a single-point measurement is adequate.

Abstract: A blood coagulation system analysis device capable of analyzing a blood coagulation system with high accuracy, and a method and a program for analysis of a blood coagulation system are proposed. The blood coagulation system is observed as a temporal change in permittivity before the viscoelasticity manifestation timing (timing at which blood starts to clot from the viewpoint of viscoelasticity (in greater detail, timing at which active polymerization of fibrin monomers starts)). A permittivity of blood which is positioned between a pair of electrodes is measured at predetermined time intervals after the anticoagulant effect acting on the blood is ended, and from the measurement result, a degree of the action of the blood coagulation system is analyzed.

Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject.

Abstract: A method of selecting a stent for implantation in the circulatory system of a human being includes the steps of determining a threshold level of platelet hyper-coaguability (PHC). One marker of PHC is platelet-fibrin mediated clot strength (MA) of blood. MA above a threshold demonstrates a risk of restenosis that is relatively high. In practicing the method, a sample of blood is obtained from a patient who requires implantation of a stent, the blood sample is tested for its platelet-fibrin mediated clot strength, the clot strength of the blood sample is compared with the threshold level; if the blood sample has a clot strength below the threshold level, selecting a bare metal stent, and if the blood sample has a clot strength at or above the threshold level, selecting a drug-eluting stent. The method includes, in a preferred embodiment, use of a viscoelastic monitor to perform the testing step. Other markers of PHC may also be employed such as measurement of thrombin generation and/or platelet reactivity.

Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of hemostasis therapies including anticoagulation therapies such as direct thrombin inhibition therapies.

Abstract: The present invention provides a method for testing quickly and easily the manner in which an antithrombotic agent inhibits the acceleration of blood coagulation when a platelet agonist causes acceleration of blood coagulation. The invention is a test method wherein a system in which an anticoagulant is added to a portion of blood sampled from a patient being administered an antithrombotic agent (X system blood), and a system in which an anticoagulant and adenosine diphosphate or collagen are added to a portion of the abovementioned blood (Y system blood) are simultaneously measured by thromboelastograph; and the efficacy of the antithrombotic agent is assessed by comparing the R values of the X system blood and the Y system blood. If the R value of the Y system blood is not found to differ significantly from the R value of the X system blood, the drug is judged to be working. Adenosine diphosphate and collagen can be used as the anticoagulant.

Abstract: In order to be able still more precisely to determine the blood clotting activity in a patient according to the invention there is provided a method of extracorporeal determination of the blood clotting activity of a blood sample of an individual, in which the clotting time which elapses until the blood sample reaches a given degree of clotting or the degree of clotting reached by the blood sample within a given time is measured or in which in a corresponding manner the fibrinolysis time or the degree of fibrinolysis of a blood sample which has previously clotted to a certain degree is measured, the method being characterised in that measurement of the clotting/fibrinolysis time or the degree of clotting/fibrinolysis is effected with the exclusion of air.

Abstract: A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject.

Abstract: A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyser.

Abstract: Methods, apparatus and systems for characterizing changes in at least one physical property of soft tissue. A series of acoustic pulses is generated and directed into the soft tissue such that at least one of the pulses is of sufficiently high intensity to induce physical displacement of the tissue. Waves reflected off the tissue, or a flexible member that moves with the tissue, are received and measured to estimate at least one characteristic of the physical displacement induced thereby. Repetition of the generating, receiving and estimating steps provides characterization of the at least one physical property over time. Methods, apparatus and systems for characterizing at least one physical property of blood, by generating a series of acoustic pulses and directing the series of pulses into the blood such that at least one of the pulses is of sufficiently high intensity to induce physical displacement of the blood.

Abstract: A method and device for blood hemostasis analysis is disclosed. A blood sample is displaced to reach a resonant state. The resonant frequency of the blood sample is determined before, during and after a hemostasis process. The changes in the resonant frequency of the blood sample are indicative of the hemostasis characteristics of the blood sample.

Abstract: The present invention provides a reagent for measuring clotting time including a nonionic surfactant, a nickel ion and a tissue factor. A method for stabilizing a tissue factor, and use of a nonionic surfactant and a nickel salt for stabilizing a tissue factor are also disclosed.

Abstract: An acoustic blood analyzer with a transducer section of acoustic biosensors for measurement of blood properties including, but not limited to blood coagulation, platelet function and various blood disorders in a blood sample is provided. Methods for use of the blood analyzer in measurement of blood properties are also provided.

Abstract: Embodiments of the present invention relate to a system and method for in vivo measurement of blood parameters by processing analog electrical signals from a plurality of photodetectors. In some embodiments, it is possible to determine one or more blood parameters according to (i) a first electrical signal from a first detector and (ii) a second electrical signal from a second photodetector. A difference analog electrical signal is generated, indicative of a difference between the light response signal at the first location and light response signal at the second location, is generated. One or more blood parameters may be detected according to the difference analog electrical signal.

Abstract: A method of measuring blood clotting ability of a patient. A known volume of blood is dispensed on a reference disc of blotter paper, such that at least one reference blotch is formed on the reference disc. The surface area of the reference blotch formed on the reference disc, such that a relationship between the volume of blood and the surface area of the reference blotch can be obtained. An incision is made at the patient. A piece of blotter paper to the incision is applied to the incision to collect blood flowing therefrom, such that at least one blotch is formed on the piece of blotter paper. The surface area of the blotch formed on the piece of blotter paper is measured. The volume of the blood absorbed blood by the blotter paper is calculated according to the relationship between the blood volume and the surface area of the blotch.

Abstract: Apparatus and method for analysing a biological fluid sample to determine a disturbance of haemostasis resulting in a change of viscosity.